Shilpa Medicare kills European Aflibercept push, defers Unicycive revenue to FY28
Strong FY26 results couldn't mask a conference call full of delays. Pipeline programs are sliding and the margin target is off the table.
— 4 earlier stories on Shilpa Medicare Ltd. →What's new
- Shilpa Medicare abandoned European Phase III trials for Aflibercept due to cost.
- Human studies for alopecia drug SMLTOP09 have been postponed.
- Revenue from Unicycive Therapeutics pushed out to FY28.
Why this matters
Three pipeline setbacks in one call erased the narrative of a clean FY26. Scrapping the European Aflibercept program removes a major potential revenue stream from the near-term view, while deferring Unicycive revenue leaves a gap. Management's refusal to guide on its own 35% EBITDA margin target makes the pipeline losses harder to stomach.
What we're watching
- Whether Shilpa finds a partner or new strategy for Aflibercept outside Europe.
- Revised timelines for SMLTOP09 human studies and their revenue impact.
- How the company will close the FY27 revenue gap without Unicycive.
The full read
FY26 was strong. Revenue up 30%, EBITDA up 40%. But the conference call told a different story. Shilpa Medicare killed its European push for Aflibercept, postponed human studies for SMLTOP09, and deferred Unicycive revenue to FY28. Three pipeline hits in one call. Management then refused to guide on its own 35% EBITDA margin target, calling it ambitious. The financials are solid. The future just got smaller and later.
Questions answered
- Why did Shilpa Medicare abandon the European Aflibercept trials?
- Management cited cost concerns for ending the Phase III program. The move eliminates a near-term path to market for the ophthalmic drug in Europe, leaving the program's future uncertain.
- How significant is the Unicycive revenue deferral?
- Revenue expected in FY27 is now pushed to FY28, removing a near-term growth driver. This extends the timeline for returns from a key partnership.
- What does the 35% EBITDA margin target comment mean?
- By calling the target ambitious and declining to provide numerical guidance for FY27, management distanced itself from achieving that margin level. The target is effectively off the table.
- Are the strong FY26 results now irrelevant?
- No, they provide a financial cushion. But the conference call revealed multiple pipeline delays and deferred revenue, pointing to a more difficult growth path ahead that outweighs the past performance.
Story so far
All notes on SHILPAMED →- 22 May 2026 · 5:23 PM IST Shilpa Medicare kills European Aflibercept push, defers Unicycive revenue to FY28
- 1d ago Shilpa Medicare buys 30% of Spanish biotech for €7M, chases a brain-cancer therapy
- 8d ago Shilpa Medicare drops Aflibercept Europe trial, delays alopecia drug
- 12d ago Shilpa Medicare profit hits ₹108 cr as pharma operations turn around
- 12d ago Shilpa Medicare profit triples to ₹243 cr